A phase II study of the combination of liposomal doxorubicin (LD) and gemcitabine (G) in patients with relapsed ovarian cancer after chemotherapy containing platinum compounds.

被引：0
|
作者：
Gambino, A [1 ]
Tognon, G [1 ]
Galleri, G [1 ]
Agoni, L [1 ]
Pecorelli, S [1 ]
机构：
[1] Univ Studi, Brescia, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：492S / 492S
页数：1
相关论文
共 50 条
  • [41] Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer Reply
    Hamanishi, Junzo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (05) : 523 - 524
  • [42] Comparison of the effectiveness of liposomal doxorubicin and gemcitabine in patients with platinum-sensitive recurrent ovarian cancer receiving third-line chemotherapy
    Bayram, E.
    Khatib, G.
    Kucukgoz-Gulec, U.
    Guzel, A. B.
    Vardar, M. A.
    Paydas, S.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (14) : 6618 - 6626
  • [43] Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
    William P. McGuire
    Richard T. Penson
    Martin Gore
    Antonio Casado Herraez
    Patrick Peterson
    Ashwin Shahir
    Robert Ilaria
    BMC Cancer, 18
  • [44] Randomized phase II study of the PDGFR antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
    McGuire, William P.
    Penson, Richard T.
    Gore, Martin
    Herraez, Antonio Casado
    Peterson, Patrick
    Shahir, Ashwin
    Ilaria, Robert, Jr.
    BMC CANCER, 2018, 18
  • [45] A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer
    Itani, Yoshio
    Hosokawa, Kenichi
    Ito, Kimihiko
    Takeuchi, Satoshi
    Tabata, Tsutomu
    Tsubamoto, Hiroshi
    Fujita, Hiroyuki
    Akiyama, Minoru
    Adachi, Susumu
    ANTICANCER RESEARCH, 2009, 29 (05) : 1521 - 1526
  • [46] Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients
    Lund, B
    Hansen, OP
    Neijt, JP
    Theilade, K
    Hansen, M
    ANTI-CANCER DRUGS, 1995, 6 : 61 - 62
  • [47] A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
    Wu, Lingying
    Wang, Jing
    Wang, Li
    Lu, Weiguo
    Wang, Ke
    Lin, An
    Li, Ning
    Li, Li
    Su, Ning
    Xie, Shuang
    Jiang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients
    Fabi, A
    Ferretti, G
    Papaldo, P
    Salesi, N
    Ciccarese, M
    Lorusso, V
    Carlini, P
    Carpino, A
    Mottolese, M
    Cianciulli, AM
    Giannarelli, D
    Sperduti, I
    Felici, A
    Cognetti, F
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (05) : 615 - 623
  • [49] Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: A phase II Austrian AGO study
    Petru, E.
    Angleitner-Boubenizek, L.
    Reinthaller, A.
    Delbl, M.
    Zeimet, A. G.
    Volgger, B.
    Stempfl, A.
    Marth, C.
    GYNECOLOGIC ONCOLOGY, 2006, 102 (02) : 226 - 229
  • [50] Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a Phase II study
    Rigatos, SK
    Tsavdaridis, D
    Athanasiadis, A
    Stathopoulos, JG
    Stathopoulos, GP
    ONCOLOGY REPORTS, 2003, 10 (06) : 1817 - 1819
12345